APA (7th ed.) Citation

Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., . . . Wolff, R. A. (2011). Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression. Journal of clinical oncology, 29(22), 3037-3043. https://doi.org/10.1200/JCO.2010.33.8038

Chicago Style (17th ed.) Citation

Crane, Christopher H., et al. "Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression." Journal of Clinical Oncology 29, no. 22 (2011): 3037-3043. https://doi.org/10.1200/JCO.2010.33.8038.

MLA (9th ed.) Citation

Crane, Christopher H., et al. "Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression." Journal of Clinical Oncology, vol. 29, no. 22, 2011, pp. 3037-3043, https://doi.org/10.1200/JCO.2010.33.8038.